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A BST R AC T   
 
Aim: To investigate the incidence of unexpected malignant and premalignant gynecological 
pathological findings among women who underwent hysterectomy due to pelvic organ prolapse 
(POP). 
Methods: In this retrospective study, the medical reports of women who underwent hysterectomy for 
POP between 2007 and 2019 were investigated to reveal unexpected malignant and premalignant 
lesions. The possible relationship between pathological results and other variables was evaluated 
statistically.  
Results: The hysterectomy was performed by abdominal (160, 30.53%), laparoscopic (62%, 11.83%) 
and vaginal approaches (302, 57.63%) in 524 patients with POP indication. Thirty five patients 
(6.67%) had unexpected premalignant or malignant pathological findings found on hysterectomy 
specimens. Simple hyperplasia  was found in 18 patients (3.44%), complex hyperplasia in two 
patients (0.38%); CIN-1 (LSIL) low grade cervical intraepithelial dysplasia in nine patients (1.7%), 
CIN-II, moderate dysplasia in two patients  (0.38%); CIN-III, severe dysplasia in one patient (0.19%); 
vaginal carcinoma in two patients (0.38%) and endometrial carcinoma in one patient (0.19%). In the 
vaginal hysterectomy group, the incidence of unsuspected gynecological malignancy was founded at 
the rate of 0.57% (3/524) and the percentage of the group was significantly higher than laparotomic 
and laparoscopic hysterectomy groups. Statistically significant difference was not found between the 
groups with respect to unexpected uterine malignancy.  
Conclusion: Women without abnormal vaginal bleeding do not have high risk of premalignant or 
malignant pathological reporting after uterovaginal prolapse surgery, however it should not be 
neglected. 
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Introduction 
Pelvic organ prolapse (POP) is a common 
health problem which has significant negative 
effects on women’s life quality. POP is seen in 
approximately 30-40% of women who had 
given birth. The lifetime risk of surgery for POP 
in the general female population is 
approximately 19% [1]. Vaginal hysterectomy 
(VH) is the most common procedure for the 
surgical treatment of uterovaginal prolapse 
(UVP) [2,3].  Gynecologists usually encounter 
POP during uterine conservation surgery [4]. 
However, many surgeons are unwilling to 
preserve the uterus during POP surgery, since 
there may be lesions that develop later and 
require uterine evaluation and /or 
hysterectomy. 
In the literature, risk of unsuspected 
gynecological malignancy after hysterectomy 
for POP ranges between 0.0 and 0.9 % [5,6].  
Hence, this study aimed to investigate the 
incidence of malignant and/or premalignant 
pathological results of women with normal 
cervical cytology and transvaginal ultrasound 
who underwent hysterectomy for POP. 
 
Materials and Methods 
This retrospective cohort was conducted after 
getting approval from the ethics committee of 
Abant İzzet Baysal University (Decision no: 
2019/325). All patients were selected from İzzet 
Baysal State Hospital and Abant İzzet Baysal 
University Hospital, who underwent 
hysterectomy for POP between Jan. 1, 2007 and 
November. 14, 2019. Patients were evaluated 
according to International Classification of 
Diseases, Revision Ten codes. Data were 
collected from a retrospectively maintained 
departmental billing database. The database 
access granted from International Classification 
of Disease codes, current procedural 
terminology. Medical records of the patients 
including clinical characteristics and past 
medical histories were collected from the 
hospital database. Pathology reports were 
reviewed for the final pathology.  
Patients  who underwent hysterectomy 
according to International Classification of 
Disease Revision Ten codes (ICD 10)  N 81.4 
(Uterovaginal prolapse, unspecified), N 81 
(Female genital prolapse), N81.2 (Incomplete 
uterovaginal prolapse), N81.3 (Complete 
uterovaginal prolapse), N81.8 other (Female 
genital prolapse) and N81.9 (Female genital 
prolapse, unspecified) diagnoses were included 
in this study. In addition, patients enrolled to 
this study had a normal cervicovaginal smear 
test in the last one year or a negative 
cervicovaginal cytology test and human 
papilloma virus within three years before 
surgery. Women without abnormal uterine 
bleeding symptoms or abnormal endometrial 
findings do not routinely undergo endometrial 
biopsies in daily surgical practice. Patients with 
premalignant and / or malignant adnexal, 
uterine or cervical pathology were excluded 
from the study. Women whose last menstruation 
was retarded more than 1 year, who were 
postmenopausal and over 40 years old were 
also discarded. Menorrhagia, intermenstrual 
bleeding and postmenopausal bleeding were 
considered as abnormal uterine bleedings. 
Treatment approaches in this study were 
recorded as laparoscopic hysterectomy, vaginal 
hysterectomy, and abdominal hysterectomy.  
 
Statistical analysis 
Data analysis was performed using SPSS 
version 23.0 (SPSS Inc. USA). Student t-test 
was used to evaluate the possible relationship 
between pathologic results and other variables. 
Chi-square test was used to evaluate abnormal 
pathologic results between each hysterectomy 
type. The results were assessed within 95% 
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confidence interval. A p value <0.05 was 
considered as statistically significant. 
 
Results  
Five hundred and twenty four hysterectomies 
with the indication of POP were performed 
during the study period, including abdominal 
(160, 30.53%), laparoscopic (62, 11.83%) and 
vaginal approaches (302, 57.63%) (Table 1). 
The mean age of the women in this study was 
51.34 ± 9.62 years (50.5-52.2, 95% CI). Table 
2 shows preoperative diagnosis of patients.  
 
Table 1. Surgical procedures for pelvic organ 
prolapse (POP) treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary indications for hysterectomy were (N 
81.4) Uterovaginal prolapse, unspecified (275, 
52.48%), (N 81) Female genital prolapse (101, 
19.27%), (N81.2) Incomplete uterovaginal 
prolapse (61, 11.64%), (N81.3) Complete 
uterovaginal prolapse (51, 9.73%), (N81.8) 
other Female genital prolapse (24, 4.58%) and 
(N81.9) Female genital prolapse unspecified 
(12, 2.29%).    In      preoperative       screening,  
Table 2. Distribution of preoperative diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eighteen patients (3.44%) were detected to have 
abnormal uterine bleeding symptoms. None of 
them was postmenopausal.  
Preoperative diagnostic evaluation with 
ultrasound scanning and/or endometrial biopsy 
was negative for malignant and premalignant 
disease. Women with no symptoms or abnormal 
gynecological examination do not routinely 
undergo endometrial sampling in daily surgical 
practice. 
Table 3 shows pathological results after 
hysterectomy of the study subjects. Thirty five 
patients (6.67%; 95% CI, 5.7–7.2) have 
unsuspected premalignant or malignant 
gynecological pathological result found after 
hysterectomy. Simple hyperplasia without 
atypia were detected in 18 patients (3.44%; 
95% CI, 2.34–4.56), complex hyperplasia 
without atypia in two patients (0.38%; 95% CI, 
0.21–1.49), CIN-I (cervical intraepithelial 
neoplasia) in nine patients (1.7%; 95 CI, 1.5-
1.9) ,  CIN-II in two patients  (0.38%; 95% CI, 
0.21–1.49), one CIN-III in one patient (0.19%; 
95% CI, 0.11–0.27), vaginal carcinoma in two 
patients (0.38% ;95% ,0.21-1.49) and 
endometrial carcinoma in one patient 0.19%; 
95% CI, 0.11–0.27) after pathology reporting.  
                                                        Ekici et al. Exp Biomed Res 2020; 3(1):56-62 
   
 
59 
 
Table 3. The pathology results after the 
hysterectomy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These unexpected premalign gynecological 
pathologies (6.09%) were detected in 
premenopausal women. In total, women 
diagnosed with unexpected gynecological 
malignancies after a hysterectomy was three 
(0.57%). These included two vaginal squamous 
cell carcinomas (0.38%) and one endometrioid 
type of endometrium adenocarcinoma (0.19%). 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of the numbers of Unexpected 
Uterine Malignancy (UUM) among abdominal, 
laparoscopic and vaginal hysterectomy are 
shown in table 4. Statistically significant 
difference was not found with respect to mean 
age of abdominal hysterectomy, laparoscopic 
and vaginal hysterectomy groups (51.75± 9.83, 
51.32± 9.51 and 51.39± 10.04, respectively, 
p=0.299).  
No signiﬁcant difference was observed with 
respect to the incidence of patients diagnosed 
with UUM after hysterectomy in laparotomic, 
laparoscopic and vaginal hysterectomy groups 
(laparotomy, 0 [0.0 %]; laparoscopy, 0 [0.0 %]; 
vaginal, 1 [0.19%] p=0.077). The incidence of 
unsuspected gynecological malignancy after 
hysterectomy was 0.57 % (3/ 524) which was 
significantly higher in vaginal hysterectomy 
group (p=0.01). The incidences of UUM, 
unsuspected endometrial malignancy and 
unexpected gynecological malignancy other 
than endometrial malignancy were 0.19% 
(1/524 patients), 0.19% (1/524 patients) and 
0.38% (2/524 patients), respectively. 
In the cohort of women found to have an 
unanticipated uterine malignancy after 
hysterectomy, the median age at the time of 
diagnosis was 58 years (range 51–65). The age 
of unsuspected endometrial   malignancy   case  
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was 51 years, her preoperative endometrial 
thickness was 15mm, and preoperative 
endometrial sampling pathologic result was 
proliferative endometrium and postoperative 
hysterectomy pathologic result was stage 0 
endometrioid type adenocarcinoma grade I. 
This patient did not receive any additional 
surgery or treatments at the time of observation.  
Vaginal squamous cell carcinoma cases were 
determined to vaginal pathologic specimen who 
underwent vaginal hysterectomy. One of these 
cases was 58 and the other was 66 years old. In 
these two patients, vaginal prolapse was present 
for more than 10 years and they underwent 
vaginal hysterectomy with a diagnosis of stage 
4 uterovaginal prolapse. The result of 
postoperative pathology in which tissues were 
extracted from the posterior vaginal walls 
revealed Stage 2A squamous cell carcinoma 
well differentiated type. These patients received 
radiotherapy after diagnosis. No surgical 
treatment was performed again. 
 
Discussion 
The results of uterine protective surgery for 
POP treatment showed very low risk of 
unexpected premalignant or malignant 
gynecologic disease (6.67%). The unsuspected 
malignancy risk was 0% among premenopausal 
women in our patient group. Though, 6.09% of 
premenopausal women were diagnosed with 
endometrial hyperplasia or cervical 
intraepithelial neoplasia after hysterectomy and 
reconstructive surgery, only 0.57 % of the 
patients had detected gynecological 
malignancy. The unexpected uterine 
malignancy risk was 0.19% and unexpected 
gynecological malignancy other than uterine 
malignancy risk was 0.38% in our study. 
Patients without abnormal uterine bleeding 
symptoms had minimal risk of unsuspected 
disease.  On the other hand, postmenopausal 
women suspected of bleeding patterns have 
significant risk for unsuspected malign disease 
and are not good candidates for uterine 
conservation [5]. But, postmenopausal patients 
without abnormal uterine or vaginal bleeding 
have a low risk of abnormal pathology (0.57%). 
Incidence rates were reported to be 0–0.9 % in 
previous studies (Table 5). Frick et al. [6] 
reviewed 644 hysterectomy cases with POP and 
found two unsuspected malignancies (0.3%). 
They found cancer cases in patients with 
postmenopausal bleeding. Ram et al. found that 
very few women undergoing POP surgery had 
undiagnosed serious endometrial pathologic 
results (0.7%), with five of them incidentally 
diagnosed with uterine cancers (0.6%) [7]. 
These cancer cases were detected in 
postmenopausal patients with abnormal 
endometrial thickness without abnormal uterine 
bleeding. Similar to this study, we also detected 
unexpected endometrial cancer cases were 
detected in postmenopausal patients with 
higher endometrial thickness and without 
postmenopausal hemorrhage. In the present 
study, the rate of unexpected endometrial 
malignancy was 0.19% and vaginal squamous 
cell carcinoma was 0.38% in patients who 
underwent vaginal hysterectomy with the 
diagnosis of UVP. Similarly; unexpected 
endometrial malignancy incidence has been 
reported between 0-0.54 percent in 
hysterectomies performed with the diagnosis of 
pelvic floor dysfunction [8-10]. Previous 
studies did not report unexpected cases of 
vaginal cancer. It may be because the vaginal 
tissue was not removed or the extracted vaginal 
tissues were not taken into pathological 
examination. 
Our results show that abnormal gynecological 
pathology risk is low after hysterectomy and 
does not show the risk of uterine, adnexal, 
vaginal or cervical     disease     for    the rest of  
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patient's life. Surgical procedure should not 
include removing of the ovarian tissue. So, 
incidentally abnormal ovarian pathology is 
expected to occur only in a few patients, even a 
little normal appearance of the ovaries is seen 
intraoperative.  
Our study had some limitations. First, this is a 
retrospective study. Second, this study does not 
provide information about ovarian pathologies, 
third, preoperative examinations are not 
performed in the same clinic and there may be 
inadequate or incomplete evaluations resulting 
from this. 
The strengths of our study are that the number 
of patients is high and that the patients with 
postmenopausal bleeding are not included. 
Conclusion 
The rate of incidentally found premalignant or 
malignant gynecological pathological findings 
in patients who underwent hysterectomy with 
the diagnoses   of    POP    were    not   frequent  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0,57%) in this study, but the risk should not be 
ignored. Therefore, patients who underwent 
surgery due to POP must be informed about the 
risk of unexpected gynecological malignancy. 
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